Salient Pharma ApS

CVR36900709

Core data

Name
Salient Pharma ApS
Address
Naverland 22, 2600, Glostrup
Founded
May 21, 2015
Employees
1Jun 2020
Locations (P-units)
1View locations
Website
www.salientpharma.com
Branch
Engroshandel med medicinalvarer og sygeplejeartikler (464610)

Keep track of Salient Pharma ApS

Get an email when we detect changes to financial reports, ownership or management. Save yourself checking the company again.
Free account

Financials

Company financials
Reporting period
2025DKK
Gross profit
-129,889
Operating profit
-129,889
Profit before tax
-218,345
Net income
-218,345
Total assets
44,526
Equity
-1,344,010
Avg. employees
0
2017–2025

Unlock financial history

Datapublica Risk Score

Locked
Assesses the risk of financial distress using the company’s accounts, history, and connections.
Company score
0 · Low100 · High

What goes into the assessment

  • Financials

  • Accounts and history

  • Owners and management

  • Company and connections

Standard: Score and risk bandPro: Also a detailed explanation of the factors

Contact

From cvr.dk

Company
4280****Show full
**@salientpharma.comShow full

Gazelle

Loading gazelle status…

Børsen Gazelle is Dagbladet Børsen's award. Datapublica is not affiliated with Børsen. Calculated statuses are Datapublica's own analysis of public CVR financial-statement data.

People

Helle BøwadtRoles
Board
TitlesBESTYRELSESMEDLEM
Søren Wang PetersenRoles
Board
TitlesBESTYRELSESMEDLEM
Ulrik SporkRoles
BoardManagement
TitlesBESTYRELSESMEDLEM • DIREKTØR

Auditor

GE REVISION & RÅDGIVNING, REGISTRERET REVISIONSANPARTSSELSKABAuditorBenjamin Elleby JensenRoleRegistreret revisorFromJun 25, 2026
GE REVISION & RÅDGIVNING, REGISTRERET REVISIONSANPARTSSELSKABAuditor—Role—FromJun 25, 2026
Ownership33.33–49.99 %Voting rights33.33 %FromDec 31, 2023
Ownership25–33.32 %Voting rights25 %FromDec 31, 2023
Ownership15–19.99 %Voting rights15 %FromDec 31, 2023

Ultimate owners

Helle Bøwadt
Ownership through
33.33–49.99 %
Ulrik Spork
25–33.32 %
CAND.PHARM. POVL M. ASSENS FOND
Ownership through
Direct
15–19.99 %

Official sources